Infergen Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Infergen market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to the increasing prevalence of hepatitis C, a rising incidence of liver diseases, expanding healthcare infrastructure, a growing number of chronic diseases, and heightened demand for effective antiviral treatments.

Growth during the forecast period is expected to be driven by increasing awareness about hepatitis C, a rising focus on personalized medicine, advancements in chronic disease management, an emphasis on immunotherapy, and the expansion of outpatient treatment facilities. Key trends anticipated in the forecast period include advancements in drug formulations, the integration of technology in treatment management, innovations in liver disease diagnostics, the development of self-administration treatments, and the use of interferons in combination therapies.

The increasing prevalence of chronic hepatitis C is expected to propel the growth of the infergen market in the coming years. Chronic hepatitis C is a persistent infection caused by the hepatitis C virus, defined by the virus remaining in the body for more than six months. If untreated, it can lead to severe health complications such as liver damage, cirrhosis, and liver cancer. The growing prevalence of chronic hepatitis C is largely driven by higher rates of injection drug use, which promotes blood-to-blood transmission of the virus, as well as limited access to prevention and treatment services. Infergen, a pegylated form of interferon alfa-2b, benefits patients with chronic hepatitis C by activating the immune system to combat the virus, improving liver function, reducing viral load, and potentially achieving sustained virologic response (SVR), a critical factor in preventing liver damage and related complications. For example, in March 2024, the UK Health Security Agency reported that approximately 62,600 adults aged 16 and over in England were living with chronic hepatitis C infection in 2022. Thus, the increasing prevalence of chronic hepatitis C is driving the growth of the infergen market.

The growing demand for personalized medicine is another factor expected to significantly drive the growth of the infergen market. Personalized medicine focuses on tailoring medical treatments to fit the unique characteristics, needs, and preferences of each individual, often leveraging genetic information to enhance treatment efficacy while minimizing adverse effects. This demand is fueled by patients seeking more effective healthcare solutions designed to address their specific genetic, physiological, and lifestyle factors. Infergen (interferon alfacon-1) is employed as a personalized medicine by customizing treatment plans based on patient-specific factors such as viral load and genotype in cases of chronic hepatitis C. For example, in February 2022, the Personalized Medicine Coalition reported that twelve new personalized medications were approved that year, representing about 34% of all newly approved treatments and reflecting a significant increase from prior years. Therefore, the rising demand for personalized medicine is anticipated to drive the growth of the infergen market.

The global expansion of healthcare infrastructure is also expected to significantly contribute to the growth of the infergen market. Healthcare infrastructure encompasses the physical and organizational structures, facilities, resources, and systems necessary to deliver healthcare services. This expansion is being fueled by factors such as the aging global population, an increase in chronic diseases, and technological advancements. Healthcare infrastructure supports infergen by ensuring the availability of essential medical facilities, skilled healthcare professionals, diagnostic tools, and treatment protocols, enabling effective administration of the drug, monitoring of patient progress, and management of potential side effects to achieve optimal outcomes for chronic hepatitis C patients. For instance, in September 2024, Cross River Therapy reported that the U.S. pharmaceutical industry generated $550 billion in revenue, with Americans spending $576.9 billion on medicine in 2021, and projected spending expected to rise to $605-$635 billion by 2025. Hence, the global expansion of healthcare infrastructure is driving the growth of the infergen market.

The key company operating in the infergen market is Amgen Inc.

North America was the largest region in the infergen market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in infergen report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the infergen market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Infergen (Interferon alfacon-1) is a recombinant type-I interferon primarily used to treat chronic hepatitis C virus infection in adults with compensated liver disease. It is a synthetic form of interferon produced through genetically modified Escherichia coli bacteria, designed to replicate the natural interferons found in the human body.

The primary patient demographics for infergen include pediatric patients, adult patients, and high-risk groups. Pediatric patients are individuals from infancy to adolescence, typically under 18 years of age. Infergen (Interferon alfacon-1) is used in pediatric patients to treat chronic hepatitis C by stimulating the immune system to combat the virus and minimize liver damage. It is applied in chronic hepatitis C treatment and combination therapy and is distributed through channels such as hospitals, specialty clinics, online pharmacies, and pharmacies.

The infergen market research report is one of a series of new reports that provides infergen market statistics, including the infergen industry's global market size, regional shares, competitors with a infergen market share, detailed infergen market segments, market trends and opportunities, and any further data you may need to thrive in the infergen industry. This infergen market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The infergen market includes sales of interferon alfacon-1 injection products available in single-use vials containing 9 mcg and 15 mcg formulations, and combination therapy kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.